Wilkes Barre Hospital Company LLC
Wilkes Barre Hospital Company LLC was paid $7.41M by Medicaid between Jan 2018 and Dec 2024, across 258 billing codes. Its largest line is 99284, emergency room visit (serious) — 25% of everything it billed.
WILKES BARRE, PA 18702
Next to other General Acute Care Hospital providers in Pennsylvania
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,065 | $28K | |
| 2019 | 1,646 | $36K | |
| 2020 | 34,798 | $704K | |
| 2021 | 148,693 | $3.27M | |
| 2022 | 43,241 | $1.19M | |
| 2023 | 43,834 | $1.21M | |
| 2024incomplete | 32,861 | $978K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 25% | 18,823 | 17,907 | $1.85M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 14,867 | 14,353 | $1.14M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 7.9% | 10,022 | 9,476 | $588K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.3% | 4,885 | 4,686 | $540K |
| G0378 | Hospital observation service, per hour | 4.2% | 458 | 424 | $312K |
| 80053 | Comprehensive metabolic panel | 3.9% | 30,957 | 28,892 | $292K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.9% | 4,068 | 3,781 | $291K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.0% | 31,925 | 29,515 | $152K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.6% | 6,289 | 6,125 | $121K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 2,184 | 2,109 | $104K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.3% | 1,792 | 1,739 | $96K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 1,054 | 1,034 | $79K |
246 more codes
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 6,853 | $68K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,869 | $68K |
| 80061 | Lipid panel | <1% | 5,488 | $62K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 429 | $60K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,840 | $57K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,648 | $50K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,529 | $42K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 534 | $39K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 772 | $39K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,556 | $37K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,467 | $36K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,225 | $36K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,055 | $32K |
| 0012A | <1% | 731 | $30K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 839 | $29K |
| 84702 | <1% | 1,847 | $28K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,045 | $28K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,447 | $28K |
| G0379 | Direct admission of patient for hospital observation care | <1% | 26 | $27K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,185 | $27K |
| 81001 | <1% | 11,431 | $27K | |
| 84703 | <1% | 2,713 | $26K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 206 | $24K |
| 84484 | <1% | 3,270 | $24K | |
| 83735 | <1% | 4,117 | $23K | |
| 80050 | General health panel | <1% | 572 | $22K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 896 | $20K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 387 | $20K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 507 | $19K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,393 | $19K |
| 36415 | Collection of venous blood by venipuncture | <1% | 14,130 | $18K |
| 85027 | <1% | 3,070 | $18K | |
| 80074 | <1% | 357 | $17K | |
| 0240U | <1% | 603 | $17K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,523 | $17K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 107 | $17K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 758 | $16K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 303 | $16K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 329 | $15K |
| 85610 | <1% | 5,507 | $15K | |
| 76641 | <1% | 268 | $15K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,169 | $15K |
| 76830 | Ultrasound, transvaginal | <1% | 313 | $13K |
| 86780 | <1% | 885 | $13K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 487 | $13K |
| 88342 | <1% | 498 | $12K | |
| 84439 | <1% | 1,846 | $12K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 439 | $12K |
| 83690 | <1% | 2,833 | $11K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 361 | $11K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 469 | $11K |
| 93975 | <1% | 99 | $11K | |
| 76536 | <1% | 281 | $11K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 239 | $10K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 310 | $10K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,272 | $10K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 513 | $10K |
| 83880 | <1% | 435 | $10K | |
| 93971 | <1% | 167 | $10K | |
| 71250 | <1% | 190 | $10K | |
| 87040 | <1% | 847 | $9K | |
| 82607 | <1% | 837 | $9K | |
| 87070 | <1% | 1,295 | $8K | |
| 82728 | <1% | 817 | $8K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 172 | $8K |
| 85730 | <1% | 1,418 | $8K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 51 | $8K |
| 84153 | <1% | 350 | $8K | |
| 84481 | <1% | 344 | $7K | |
| 74018 | <1% | 563 | $7K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 40 | $7K |
| 84403 | <1% | 252 | $7K | |
| 70486 | <1% | 122 | $6K | |
| 93970 | <1% | 97 | $6K | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 219 | $6K |
| 86850 | <1% | 860 | $6K | |
| 97161 | <1% | 167 | $6K | |
| 83540 | <1% | 899 | $6K | |
| 81025 | <1% | 1,659 | $6K | |
| 83605 | <1% | 1,030 | $6K | |
| 93880 | <1% | 101 | $6K | |
| 87186 | <1% | 792 | $5K | |
| 86803 | <1% | 306 | $5K | |
| 76775 | <1% | 175 | $5K | |
| 73564 | <1% | 297 | $5K | |
| 84146 | <1% | 224 | $5K | |
| 82043 | <1% | 817 | $5K | |
| 97035 | <1% | 627 | $5K | |
| 82077 | <1% | 1,184 | $5K | |
| 82570 | <1% | 838 | $5K | |
| 93017 | <1% | 172 | $4K | |
| 72100 | <1% | 250 | $4K | |
| 77065 | Tomosynthesis, mammo | <1% | 88 | $4K |
| 87077 | <1% | 682 | $4K | |
| 80164 | <1% | 264 | $4K | |
| 86618 | <1% | 197 | $4K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 490 | $4K |
| 86762 | <1% | 227 | $4K | |
| 73610 | <1% | 249 | $4K | |
| 82248 | <1% | 683 | $4K | |
| 86038 | <1% | 299 | $4K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 26 | $4K |
| 88313 | <1% | 212 | $4K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 12 | $4K |
| 0002A | <1% | 91 | $4K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 59 | $4K |
| 82550 | <1% | 649 | $4K | |
| 73030 | <1% | 320 | $4K | |
| 86140 | <1% | 1,343 | $3K | |
| 86900 | <1% | 1,059 | $3K | |
| 86901 | <1% | 1,059 | $3K | |
| 77066 | Tomosynthesis, mammo | <1% | 42 | $3K |
| 87522 | Neg quan hep c or qual rna | <1% | 87 | $3K |
| 87340 | <1% | 255 | $3K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 169 | $3K |
| 82746 | <1% | 315 | $3K | |
| 0011A | <1% | 70 | $3K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 15 | $3K |
| 76642 | <1% | 82 | $3K | |
| 85379 | <1% | 331 | $3K | |
| 73630 | <1% | 293 | $3K | |
| 72110 | <1% | 146 | $3K | |
| 73130 | <1% | 263 | $3K | |
| 84144 | <1% | 159 | $3K | |
| 72131 | <1% | 45 | $3K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 45 | $3K |
| 83001 | <1% | 145 | $2K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 14 | $2K |
| 90715 | <1% | 180 | $2K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 58 | $2K |
| 83550 | <1% | 574 | $2K | |
| 83525 | <1% | 203 | $2K | |
| 85652 | <1% | 848 | $2K | |
| 84436 | <1% | 260 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 47 | $2K |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 346 | $2K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 141 | $2K |
| 80076 | <1% | 252 | $2K | |
| 82105 | <1% | 103 | $2K | |
| 82784 | <1% | 101 | $2K | |
| 82150 | <1% | 478 | $2K | |
| 88360 | <1% | 63 | $2K | |
| 87088 | <1% | 258 | $2K | |
| 86317 | <1% | 69 | $2K | |
| 83970 | <1% | 57 | $2K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 12 | $1K |
| 80178 | <1% | 221 | $1K | |
| 84402 | <1% | 57 | $1K | |
| 82950 | <1% | 232 | $1K | |
| 84550 | <1% | 313 | $1K | |
| 86431 | <1% | 212 | $1K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 82 | $1K |
| 73502 | <1% | 101 | $1K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 34 | $1K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 226 | $1K |
| 73110 | <1% | 126 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 147 | $1K |
| 82962 | <1% | 975 | $1K | |
| 80069 | <1% | 158 | $1K | |
| 72040 | <1% | 81 | $1K | |
| 83002 | <1% | 62 | $1K | |
| 80143 | <1% | 223 | $883.00 | |
| 84425 | <1% | 142 | $878.72 | |
| 84100 | <1% | 207 | $855.45 | |
| 82330 | <1% | 98 | $828.08 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,682 | $825.58 |
| 96376 | <1% | 17 | $821.52 | |
| 86696 | <1% | 32 | $805.71 | |
| 80179 | <1% | 196 | $772.12 | |
| 82140 | <1% | 206 | $771.33 | |
| 93226 | <1% | 25 | $719.44 | |
| 84590 | <1% | 63 | $715.35 | |
| 86695 | <1% | 33 | $704.17 | |
| 82977 | <1% | 90 | $694.93 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 372 | $671.98 |
| 82565 | <1% | 114 | $650.86 | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,375 | $649.66 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 47 | $639.34 |
| 83655 | <1% | 62 | $633.50 | |
| 88341 | <1% | 15 | $612.54 | |
| 84156 | <1% | 214 | $601.97 | |
| 77061 | <1% | 12 | $553.52 | |
| 86787 | <1% | 28 | $511.66 | |
| 82670 | <1% | 25 | $502.12 | |
| 0001A | <1% | 12 | $500.00 | |
| 86255 | <1% | 30 | $481.66 | |
| 12001 | <1% | 24 | $469.24 | |
| 12011 | <1% | 13 | $444.19 | |
| 73140 | <1% | 47 | $413.80 | |
| 85018 | <1% | 175 | $412.66 | |
| 83721 | <1% | 42 | $390.91 | |
| 71100 | <1% | 26 | $374.57 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,665 | $339.78 |
| 94726 | <1% | 12 | $329.76 | |
| 88304 | <1% | 136 | $305.45 | |
| 97165 | <1% | 13 | $274.70 | |
| 85014 | <1% | 102 | $267.19 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 295 | $257.84 |
| 72050 | <1% | 12 | $242.41 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,690 | $240.40 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 580 | $235.31 |
| 73080 | <1% | 18 | $214.36 | |
| 72072 | <1% | 12 | $213.23 | |
| 93225 | <1% | 13 | $212.20 | |
| 84479 | <1% | 30 | $190.21 | |
| 82785 | <1% | 12 | $186.66 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,127 | $176.90 |
| 84466 | <1% | 14 | $162.83 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 12 | $162.33 |
| 82378 | <1% | 12 | $159.15 | |
| 84520 | <1% | 32 | $152.25 | |
| 82951 | <1% | 12 | $145.67 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 32 | $145.19 |
| 82947 | <1% | 42 | $143.53 | |
| 80177 | <1% | 14 | $141.71 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 192 | $138.83 |
| 87147 | <1% | 41 | $135.45 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 770 | $129.02 |
| 87081 | <1% | 25 | $126.36 | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 12 | $123.12 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,679 | $118.96 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 100 | $114.96 |
| 73090 | <1% | 12 | $111.15 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 308 | $109.47 |
| 73590 | <1% | 13 | $105.14 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,642 | $103.07 |
| 87486 | <1% | 12 | $98.64 | |
| 86376 | <1% | 13 | $98.52 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 73 | $67.63 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 148 | $53.83 |
| 85045 | <1% | 14 | $51.55 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 131 | $48.87 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 16 | $47.14 |
| 97116 | <1% | 15 | $46.52 | |
| 82040 | <1% | 12 | $41.60 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 26 | $36.48 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 37 | $33.66 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 125 | $26.09 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 40 | $10.49 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 171 | $1.15 |
| 91301 | <1% | 358 | $0.03 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 69 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 26 | $0.00 |
| 36430 | 0% | 18 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 122 | $0.00 |
| 91300 | 0% | 38 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Roswell Hospital Corporation | Roswell, NM | $41.27M |
| Wesley Health System LLC | Hattiesburg, MS | $37.82M |
| Metro Knoxville Hma LLC | Powell, TN | $28.70M |
| Bullhead City Hospital Corporation | Bullhead City, AZ | $28.54M |
| Iom Health System LP | Fort Wayne, IN | $27.50M |
| ST. Joseph Health System, LLC | Fort Wayne, IN | $25.43M |
| Laredo Texas Hospital Company LP | Laredo, TX | $19.46M |
| Oak Hill Hospital Corporation | Oak Hill, WV | $18.77M |
| Cocke County Hma, LLC | Newport, TN | $18.34M |
| Cleveland Tennessee Hospital Company LLC | Cleveland, TN | $16.31M |
| Jefferson County Hma LLC | Jefferson City, TN | $14.31M |
| Northwest Arkansas Hospitals, LLC | Springdale, AR | $11.46M |
| Petersburg Hospital Company LLC | Petersburg, VA | $11.20M |
| Campbell County Hma, LLC | Lafollette, TN | $10.07M |
| Warsaw Health System LLC | Warsaw, IN | $9.95M |
| Longview Medical Center LP | Longview, TX | $9.29M |
| Moberly Hospital Company LLC | Moberly, MO | $8.61M |
| Crestview Hospital Company, LLC | Crestview, FL | $8.15M |
| Kirksville Missouri Hospital Company, LLC | Kirksville, MO | $7.98M |
| Victoria of Texas LP | Victoria, TX | $7.74M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.